GlassScriptPhysician profile
Justin Jones
NPI 1942297338
$9,257.59
in general payments reported to CMS, 2019-2025
25 companies · $1,048 in 2025
The $1,048 reported for 2025 was more than what 91% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,272 · 2020: $1,256 · 2021: $2,472 · 2022: $1,527 · 2023: $608 · 2024: $1,076 · 2025: $1,048.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,714 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,714.09 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $3,774.39 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens, Misight Contact Lens |
| Biotissue Holdings INC. | $1,041.97 | 2022-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $903.79 | 2019-2021 | |
| Alcon Vision LLC | $747.89 | 2019-2025 | Precision 7, Eysuvis, Total30 |
| Kala Pharmaceuticals, INC. | $459.76 | 2021-2022 | |
| Allergan, INC. | $391.95 | 2019-2022 | |
| Synergeyes, INC. | $301.53 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $251.11 | 2022-2025 | Infuse, Vyzulta, Miebo |
| Notal Vision, INC. | $235.89 | 2022 | |
| Johnson & Johnson Vision Care, INC. | $173.85 | 2019-2021 | |
| Optovue, INC. | $148.03 | 2019 | |
| Oyster Point Pharma, INC. | $146.69 | 2022-2024 | Ryzumvi, Ryzumvi, Tyrvaya |
| Novartis Pharmaceuticals Corporation | $126.66 | 2021-2023 | |
| Maculogix, INC. | $125.60 | 2020 | |
| Optos, INC. | $106.41 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $58.80 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $57.89 | 2021-2022 | |
| Abbvie INC. | $47.81 | 2022-2023 | |
| Abb Con-Cise Optical Group LLC | $44.26 | 2019 | |
| Dompe US, INC. | $23.91 | 2025 | Oxervate |
| Horizon Therapeutics Plc | $23.45 | 2022 | |
| Harrow Eye, LLC | $23.43 | 2025 | Vevye |
| Astellas Pharma US INC | $17.04 | 2025 | Izervay |
| Heidelberg Engineering, INC. | $13.64 | 2022 | |
| Sight Sciences, INC. | $11.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.